Stocks
BioXcel Financial Statements (BTAI) |
||||||||||
| BioXcelsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 09.03.2020 | 12.03.2021 | 11.03.2022 | 16.03.2023 | 22.03.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.375 | 1.38 | 1.76 | |||
| Operating Income, bln rub | -33.6 | -82.3 | -106.9 | -159.6 | -166.3 | -144.4 | ||||
| EBITDA, bln rub | ? | -34.1 | -82.3 | -106.9 | -157.5 | -166.0 | -136.7 | |||
| Net profit, bln rub | ? | -32.3 | -82.0 | -106.6 | -171.8 | -179.1 | -153.0 | |||
| OCF, bln rub | ? | -27.3 | -66.4 | -82.2 | -135.3 | -155.0 | -120.4 | |||
| CAPEX, bln rub | ? | 0.870 | 0.316 | 0.445 | 0.139 | 0.020 | 0.020 | |||
| FCF, bln rub | ? | -28.2 | -66.7 | -82.6 | -135.5 | -155.0 | -120.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 33.6 | 82.3 | 106.9 | 160.0 | 166.1 | 140.5 | ||||
| Cost of production, bln rub | 0.156 | 0.188 | 0.297 | 0.020 | 1.58 | 1.49 | ||||
| R&D, bln rub | 25.8 | 58.0 | 52.7 | 91.2 | 82.9 | 67.5 | ||||
| Interest expenses, bln rub | 0.000 | 0.027 | 0.040 | 8.21 | 13.3 | 13.6 | ||||
| Assets, bln rub | 36.4 | 219.9 | 239.4 | 205.9 | 73.7 | 82.3 | ||||
| Net Assets, bln rub | ? | 26.9 | 206.7 | 221.7 | 76.8 | -56.5 | -72.4 | |||
| Debt, bln rub | 1.03 | 1.64 | 1.40 | 94.2 | 101.4 | 102.3 | ||||
| Cash, bln rub | 32.4 | 213.1 | 233.0 | 193.7 | 65.2 | 74.1 | ||||
| Net debt, bln rub | -31.4 | -211.5 | -231.6 | -99.6 | 36.2 | 28.2 | ||||
| Ordinary share price, rub | 14.6 | 46.2 | 20.3 | 21.5 | 2.95 | 4.00 | ||||
| Number of ordinary shares, mln | 16.3 | 21.7 | 26.4 | 28.0 | 29.1 | 30.9 | ||||
| Market cap, bln rub | 238 | 1 002 | 536 | 602 | 86 | 123 | ||||
| EV, bln rub | ? | 207 | 790 | 305 | 502 | 122 | 152 | |||
| Book value, bln rub | 27 | 207 | 222 | 77 | -57 | -72 | ||||
| EPS, rub | ? | -1.99 | -3.78 | -4.04 | -6.13 | -6.15 | -4.96 | |||
| FCF/share, rub | -1.73 | -3.07 | -3.13 | -4.84 | -5.32 | -3.90 | ||||
| BV/share, rub | 1.65 | 9.53 | 8.41 | 2.74 | -1.94 | -2.34 | ||||
| EBITDA margin, % | ? | -42 012% | -12 030% | -7 783% | ||||||
| Net margin, % | ? | -45 826% | -12 975% | -8 716% | ||||||
| FCF yield, % | ? | -11.8% | -6.65% | -15.4% | -22.5% | -180.4% | -97.5% | |||
| ROE, % | ? | -120.2% | -39.7% | -48.1% | -223.8% | 316.9% | 211.5% | |||
| ROA, % | ? | -88.9% | -37.3% | -44.5% | -83.5% | -242.9% | -185.9% | |||
| P/E | ? | -7.36 | -12.2 | -5.03 | -3.50 | -0.48 | -0.81 | |||
| P/FCF | -8.45 | -15.0 | -6.49 | -4.44 | -0.55 | -1.03 | ||||
| P/S | ? | 1 605 | 62.3 | 70.3 | ||||||
| P/BV | ? | 8.85 | 4.85 | 2.42 | 7.84 | -1.52 | -1.71 | |||
| EV/EBITDA | ? | -6.06 | -9.60 | -2.85 | -3.19 | -0.74 | -1.11 | |||
| Debt/EBITDA | 0.92 | 2.57 | 2.17 | 0.63 | -0.22 | -0.21 | ||||
| R&D/CAPEX, % | 2 965% | 18 353% | 11 844% | 65 640% | 414 665% | 337 300% | ||||
| CAPEX/Revenue, % | 37.1% | 1.45% | 1.14% | |||||||
| BioXcel shareholders | ||||||||||
